Abstract
Get full access to this article
View all access options for this article.
References
1.National Institute of Mental Health [NIMH] (1998 ). Available from: http://www.surgeongeneral.gov/library/mentalhealth/chapter4/sec1.html.
2.
Maciejewski
(1999 ). Available from: http://www.surgeongeneral.gov/library/mentalhealth/chapter4/sec1.html.
3.
Barbee
(1998 ). Available from: http://www.surgeongeneral.gov/library/mentalhealth/chapter4/sec1.html.
4.US Department of Health & Human Services (1999 ) Mental Health, A Report of the Surgeon General . Available from: http://www.surgeongeneral.gov/library/mentalhealth/toc.html.
5.Scrip (1999 ) Scrip's Complete Guide to CNS Disorders, Vol. 6 Anxiety . Scrip , New York, NY .
6.
Moroz
G.
(2004 ) ‘High-potency benzodiazepines: Recent clinical results’ , Journal of Clinical Psychiatry , 65 (Suppl. 5 ), 13 –18 .
7.
Longo
L.P.
Johnson
B.
(2000 ) ‘Benzodiazepines, Side-effects, abuse, risks and alternatives’ , American Family Physician , 61 (7 ), 2121 –2128 .
8.
Cowen
S.G.
(2004 ) Therapeutic Outlook , March, 149–165.
9.Goldman Sachs Investment Research (2004 ) Category Spotlight: Antidepressants , 15 April.
10.
Cowen
S.G.
(2004 ) op. cit. .
11.Goldman Sachs (2004 ) op. cit. .